Pilot Program Will Review First-Year Safety Data for Several NMEs
FDA outlines organizational steps and safety monitoring initiatives in response to IoM report on improving drug safety.
FDA outlines organizational steps and safety monitoring initiatives in response to IoM report on improving drug safety.